|
|
Post by mindovermatter on Apr 1, 2016 7:06:20 GMT -5
At the first of 2016 Jay had a sell rating on MNKD with a $1.00 target. On December 31, 2015 MNKD closed at $1.45. On Jan. 19th, 2016 he lowered his PT to $.25 on MNKD. Jay Olson follows only one other stock, PTLA. On December 31, 2015 he had a buy rating on PTLA and a $65.00 price target. On 12/31/2015 PTLA closed at $51.45. So if an investor or hedge fund bought PTLA and shorted MNKD using the 12/31/2015 prices, how are Jay's recommendations doing this year? PTLA made a multi year low yesterday at $18.20 and closed at $19.00. On Sunday Jay removed his buy on PTLA and placed it with a neutral and a $30.00 price target. So let's do the math on our analyst Jay Olson as of last night. If you had invested $50k in PTLA on Dec. 31, 2015 it would be worth $18,464.52. Your $50k in MNKD that you shorted on December 31, 2015 @ $1.45 would be worth $43,793.10. You would now have and account balance of $62,257.62 not including the HTB interest on your MNKD stock. If PTLA stays here and MNKD goes over $3.00, your entire investment is gone after paying the interest, or over $3.43 not including the interest. It gets better! While Jay was suggesting that clients Short or Sell MNKD, Goldman Sachs was buying, see the latest institutional holdings. What was GS doing with their PTLA holdings that Jay had a buy? GS was selling of course, see the latest on PTLA institutional holdings. I believe Jay has a middle name, drum roll please........Jay Patsy Olson! Jay doesn't have much of a track record and I think his last line of questioning during the CC exposed him as someone who seemed to be clueless or at least disingenuous. But the fact remains his price target and call on MNKD was more right than wrong. You can bitch and complain about him as I have but he's not the reason why Mannkind has under performed horribly. He didn't make the company make bad decision after bad decision such as switching devices to create the second CRL or pick Sanofi or not do a secondary when the stock price was much higher. He didn't make Mannkind pick a CEO that would only last 1 month because someone didn't do their due diligence over his non compete issue. Maybe it is time that we stop complaining about GS and start holding the Mannkind responsible for their misfortune. I know its a hard concept to swallow for many on here because it is as if Mannkind can do no wrong. But hey, I get it that it is therapeutic to blame everything and everyone else for Mannkind's poor performance. |
|
|
|
Volume
Mar 31, 2016 15:30:33 GMT -5
Post by mindovermatter on Mar 31, 2016 15:30:33 GMT -5
Nasdaq real time volume today for MNKD, 3,501,143 shares.
ten minutes prior to the close volume was, 2,195,119, so @ 130,000 shares came in the last 10 minutes of trade. www.nasdaq.com/symbol/mnkd/real-time $1.60. times 3,501,143 = $5,601,828 dollars worth of MNKD trading today.
Down almost 4% today -.07.
One year chart which isn't pretty. YTD looks good assuming one had bought in January.
|
|
|
|
Post by mindovermatter on Mar 31, 2016 11:58:56 GMT -5
Q2U, thanks for a rational response instead of a personal and emotional attack.
|
|
|
|
Post by mindovermatter on Mar 31, 2016 9:21:17 GMT -5
Just a reminder that we do not live in the best of all possible worlds and good does not always prevail over evil. I keep in mind several examples of medical treatments that have been ignored by physicians and could improve health or save thousands of lives, but are not accepted or widely used. Read this article about the history of breakthrough cancer treatments that were received by physicians as "no big deal" or modified on their whim so that they were ineffective. www.newyorker.com/wp-content/uploads/2015/12/151214_r27432-864.jpgI have had pretty serious gum disease for many years. I finally got it under control with a hydrogen peroxide rinse. The dentist, hygienists and periodontist all remark on how much better my gums are, but are not really interested in why. When I ask/tell them about hydrogen peroxide they all have the same disinterested response which includes how dangerous it can be in high concentrations (which are virtually unavailable to the consumer, who only knows the common 3% solution). Fecal transplants for patients suffering from clostridium-difficile (C. diff) could save thousands from death each year and tens of thousands from a lifetime of suffering. A recent trial of its effectiveness was halted...you know, virtually all the patients were cured so it would be immoral not to offer it to the other arm of the trial. But who is going to spend hundreds of millions of dollars to develop a "uniform, active ingredients only" treatment that the FDA might approve which could easily be copied? These treatments really present similar hurdles to regulating blood transfusions. And as an added bonus, fecal transplants are only offered as a last resort treatment after everything else has been tried, including every antibiotic on the shelf. Or you could look at the obesity epidemic. Is it really just a crisis of willpower where people can't stop overeating? I think not. How was the medical community so sure Atkins was a quack when all he was advocating was what was considered common sense in the early 20th century? One thing some these examples have in common is that the inferior treatments work, if the patients would only comply with doctors orders. If you just restrict your diet to <1500 healthy calories/day and get plenty of exercise you could loose weight. If you just brushed and flossed your way to perfect dental hygiene there would be no gum disease. And we all know that current diabetes treatments work and can keep even Type 1 diabetics alive indefinitely, if they just follow all of the protocols exactly. Which is all just to say that Al Mann was right about Afrezza being a vastly superior form of insulin therapy, but that doesn't mean doctors will prescribe it. The best way to do no harm is to "just not do it" (with apologies to Nike). And junk science has done much to make people ill. Just look at the "fat is bad" crusade. |
|
|
|
Post by mindovermatter on Mar 31, 2016 9:00:53 GMT -5
Mindovermatter, fair enough. Trust but verify. How do you suppose they got the new guy to join them from Amgen? Either they demonstrated to him that they have a viable plan and/or guaranteed cash should things not work out or he was in the process of leaving or had already left Amgen and signing on to Mannkind presented no risk. People like challenges and new opportunities. No one knows if he was Mannkind's first choice and how many applied in the first place. And nothing is guaranteed in business or in stock investment. How many here thought Mannkind would be in this position at this date and time? I am sure if those of you were polled a year back, not one of you would have said Mannkind would be in the position it is right now. Statistically, odds of success are not great especially in the cut throat pharma industry. One can only hope that Mannkind gets it right this time because it is their last shot. |
|
|
|
Post by mindovermatter on Mar 31, 2016 8:29:01 GMT -5
For those of you who do not receive the "Insulin News" email from Sanofi, I had a nice email in my inbox this morning. "Hi Scott, As you may have seen in public media communications, Afrezza® will be transferred back from Sanofi to MannKind Corporation on April 4, 2016. Future communications to you on Afrezza may come from MannKind Corporation. In addition, you may continue to receive diabetes and other health related communications from Sanofi. From April 5, 2016 onwards all questions regarding Afrezza should be directed to MannKind Corporation at 1-877-323-8505 or you can visit www.Afrezza.com." So we are on track for the timeline to return Afrezza. For now, cash is king. Matt did not sound concerned during the last call. Hopefully Matt can share some good news shortly. Pfizer gave Nectar $135mm when they discontinued Exubera. I don't believe Sanofi won't pay that kind of money to Mannkind but time will tell. Matt also stated they were happy with Sanofi while all along he knew things were going to unravel. Taking a CEOs word can be a very dangerous thing to an investor. It is more important that this failing company SHOWS us rather than tells us as it has very little success in proving it can execute successfully. And I apologize in advance to those who get emotionally hurt by straight forward facts. |
|
|
|
Post by mindovermatter on Mar 30, 2016 12:19:28 GMT -5
LOL. How's that working out for you? Besides, all the mail that goes to the SEC is just forwarded to the GS mail room where they put the letters in the recycle bin or in the bathroom for tp. mindovermatter, maybe you would be better off bashing on the YMB. Read your recent posts and all you do is bash without any helpful information here. Time to move on! Statements like TS has no value, patents have no value, I think all your comments have no value. Meaningful discussions I welcome, straight bashing with content I don't. I suggest you place me on ignore just as the SEC has done to those of you who have written to them about the manipulation of MNKD.  |
|
|
|
Post by mindovermatter on Mar 30, 2016 9:40:58 GMT -5
Several of us filed complaints on this with the SEC. Of course, no action nor acknowledgments. I hate Goldman and don't know how the gov't continues to ignore their crap except for a hand slap now and then. LOL. How's that working out for you? Besides, all the mail that goes to the SEC is just forwarded to the GS mail room where they put the letters in the recycle bin or in the bathroom for tp. |
|
|
|
Post by mindovermatter on Mar 30, 2016 9:32:18 GMT -5
Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. True, but this is largely due to the treacherous actions of SNY supported by GS, the FDA, the Insurance industry, dozens of SA articles, the Gutter.com, M.F., and by the ALMOST suicidal behavior of MNKD management. SNY shares some of the blame but let's not be blind to the fact that there are many other factors that were against Afrezza from the start. It still remains to be seen if Mannkind can do what SNY couldn't. |
|
|
|
Post by mindovermatter on Mar 30, 2016 9:26:55 GMT -5
Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. “There’s no chance that the iPhone is going to get any significant market share. No chance. It’s a $500 subsidized item.” -Steve Ballmer drugs that depend on others to prescribe and health insurance to cover it are vastly different than an electrical gadget from a company that was already doing well with other products, had support from Wall Street and had an already wide cult following. These silly comparisons are a non starter. I'll say you have a point if Afrezza actually catches on. Has it caught on after a year? No. Afrezza is a bust so far. |
|
|
|
Post by mindovermatter on Mar 30, 2016 8:19:45 GMT -5
How did this little piece of sheet, MNKD, gather such powerful enemies, and so MANY of them!! Can't say for sure but I think it all took shape back in '07 when Exubera failed and all the other inhaled insulin companies shuttered their projects sans Mannkind. Mannkind became a viable short target. Wall St saw Al as the biotech Don Quixote going after an impossible windmill of a market that didn't exist. To date, they have been right. Inahled insulin has no market. |
|
|
|
Post by mindovermatter on Mar 30, 2016 8:07:21 GMT -5
Sanofi attempted to do those quick 2 minute live Afrezza spots on local TV newscasts. Those bombed. Social media isn't going to help Afrezza other than give message board posters something to get excited about. Diabetics on diabetes message boards pretty much yawn at Afrezza. On twitter, it's the same users tweeting to each other along with two or three non users trolling others to use Afrezza. That is how sad and pathetic this has gotten. One only can hope that Mannkind has a solid strategy but considering the companies lackluster history of making good decisions, it remains to be seen if it can do anything to increase the awareness of Afrezza alone.
|
|
|
|
Post by mindovermatter on Mar 29, 2016 12:05:41 GMT -5
The other moral of the story is that bare patents are frequently worthless but the "know how" protected as trade secrets is the valuable knowledge. Most process engineering in manufacturing plants is closely guarded know how, but frequently unpatented. The two problems with patents is that they expire after a relatively short period (at least for the pharmaceutical industry where the approval process is long) and to get the patent you must disclose your methods. Often disclosure of methods is enough for a competitor to copy and tweak the process so as to be non-infringing. Which is why I have said Technosphere and its patents are likely worthless, but the manufacturing know how may not be. As any burglar knows, the most valuable jewels are the ones kept hidden. Many people place way too much importance on patents. I think we know that TS value will only come to be if drugs are sold using it. We already know Mannkind isn't having any success doing that so far. |
|
|
|
Post by mindovermatter on Mar 23, 2016 20:08:59 GMT -5
The website is blank with a square box... I am curious whot the update going to be. Something good is up..... Maybe a merger with Mannkind and the new name will be Mannkind Life Sciences!!!! |
|
|
|
Post by mindovermatter on Mar 23, 2016 19:50:14 GMT -5
This exchange was on MannKind's Facebook page. Interesting. Otto Bjorn: what they need is to break into the anti-nausea market-combine ts with zofran or similar drugs-delivering these by inhalation would be a home run for rapid action,no iv needed,and bypassing the (vomiting)gi tract
March 18 at 5:45pm
MannKind Corporation: Otto: I was able to confirm with our Chief Medical Officer the following: Palonosetron is the best in class for the 5HT3 drugs (these are the Zofran-like drugs), and MannKind believes it to be well suited for Technosphere delivery. It is currently in development within our R&D group.
March 21 at 11:06pm
www.facebook.com/MannKind-Corporation-237759248628/Wow. So many possibilities for TS. Very true. It is sad that nothing has come to fruition yet other than Afrezza. How long has TS been in the hands of Mannkind? |
|
